Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about PET: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
Knowledge base pages for this entity
| Target | Relation | Type | Str |
|---|---|---|---|
| Parkinson's Disease | biomarker_for | disease | 0.85 |
| MOLECULAR_IMAGING | regulates | phenotype | 0.72 |
| Source | Relation | Type | Str |
|---|---|---|---|
| COMPOSITE_BIOMARKER | co_associated_with | gene | 0.30 |
Hypotheses where this entity is a therapeutic target
Scientific analyses that reference this entity
neurodegeneration | 2026-04-26 | 5 hypotheses Top: 0.712
neurodegeneration | 2026-04-16 | 2 hypotheses Top: 0.933
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| GWAS of plasma NfL in East Asian cohort | exploratory | Alzheimer's disease | 0.950 | 0.00 | human patients - East Asian co | proposed | N/A |
| GWAS of plasma pTau217 in East Asian cohort | exploratory | Alzheimer's disease | 0.950 | 0.00 | human patients - East Asian co | proposed | N/A |
| Dairy intake and dementia risk in Malmö Diet and Cancer cohort | clinical | Alzheimer's disease | 0.950 | 0.00 | Swedish community-based adults | proposed | N/A |
| GWAS of plasma pTau181 in East Asian cohort | exploratory | Alzheimer's disease | 0.950 | 0.00 | human patients - East Asian co | proposed | N/A |
| GWAS of plasma GFAP in East Asian cohort | exploratory | Alzheimer's disease | 0.950 | 0.00 | human patients - East Asian co | proposed | N/A |
| KEEPS Continuation: Long-term effects of menopausal hormone therapy on | clinical | Alzheimer's disease | 0.950 | 0.00 | recently menopausal women with | proposed | N/A |
| GWAS of composite biomarker score | exploratory | Alzheimer's disease | 0.900 | 0.00 | human patients - East Asian co | proposed | N/A |
| RBG treatment in ApoE-/- atherosclerosis mouse model | validation | atherosclerosis | 0.900 | 0.00 | ApoE-/- mice | proposed | N/A |
| TDP-43 mutant mouse model cGAS/STING pathway analysis | validation | amyotrophic lateral sclerosis | 0.900 | 0.00 | TDP-43 mutant mice | proposed | N/A |
| TDP-43 mitochondrial invasion and DNA release via mPTP | exploratory | amyotrophic lateral sclerosis | 0.900 | 0.00 | cultured cells | proposed | N/A |
| TDP-43 mitochondrial invasion and mtDNA release in iPSC motor neurons | exploratory | Amyotrophic Lateral Sclerosis | 0.900 | 0.00 | iPSC-derived motor neurons | proposed | N/A |
| LPS-induced mouse model of depression with synaptic loss analysis | validation | depression | 0.900 | 0.00 | LPS-treated mice | proposed | N/A |
| Bidirectional Mendelian randomization analysis of C1Q and ischemic str | exploratory | Ischemic stroke, Atheroscleros | 0.900 | 0.00 | Human genetic association data | proposed | N/A |
| Bidirectional Mendelian randomization analysis of C1Q and ischemic str | exploratory | Ischemic stroke (large artery | 0.900 | 0.00 | human genetic data | proposed | N/A |
| cGAS/STING pathway validation in TDP-43 mutant mice | validation | Amyotrophic Lateral Sclerosis | 0.850 | 0.00 | TDP-43 mutant mice | proposed | N/A |
| C1q neutralizing antibody intervention in depression model | validation | depression | 0.850 | 0.00 | LPS-treated mice with C1q anti | proposed | N/A |
| cGAMP biomarker analysis in ALS patient spinal cord samples | exploratory | Amyotrophic Lateral Sclerosis | 0.800 | 0.00 | Human ALS patient spinal cord | proposed | N/A |
| TDP-43 pathology prevalence and distribution in AD cases | exploratory | Alzheimer's disease | 0.800 | 0.00 | human postmortem brain tissue | proposed | N/A |
| APOE4 association with TDP-43 pathology in AD | exploratory | Alzheimer's disease | 0.750 | 0.00 | human patients | proposed | N/A |
| Cognitive impact of TDP-43 pathology in AD patients | clinical | Alzheimer's disease | 0.700 | 0.00 | human patients | proposed | N/A |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Autophagy and ALS: mechanistic insights and therapeutic implications. [PMID:34057020] | Chua JP, De Calbiac H, Kabashi E, Barmad | Autophagy | 2022 | 2 |
| TDP-43 Pathology in Alzheimer's Disease. [PMID:34930382] | Meneses A, Koga S, O'Leary J, Dickson DW | Mol Neurodegener | 2021 | 2 |
| Protein transmission in neurodegenerative disease. [PMID:32203399] | Peng C, Trojanowski JQ, Lee VM | Nat Rev Neurol | 2020 | 2 |
| TDP-43 Triggers Mitochondrial DNA Release via mPTP to Activate cGAS/STING in ALS [PMID:33031745] | Yu CH, Davidson S, Harapas CR, Hilton JB | Cell | 2020 | 2 |
| Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of [PMID:30335591] | Rusmini P, Cortese K, Crippa V, Cristofa | Autophagy | 2019 | 2 |
| Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegenerat [PMID:37995685] | Litvinchuk A, Suh JH, Guo JL, Lin K, Dav | Neuron | 2024 | 1 |
| N protein of PEDV plays chess game with host proteins by selective autophagy. [PMID:36861818] | Zhai X, Kong N, Zhang Y, Song Y, Qin W, | Autophagy | 2023 | 1 |
| PIKFYVE inhibition mitigates disease in models of diverse forms of ALS. [PMID:36754049] | Hung ST, Linares GR, Chang WH, Eoh Y, Kr | Cell | 2023 | 1 |
| The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegene [PMID:37957317] | Maxine R Nelson, Peng Liu, Ayushi Agrawa | Nature neuroscience | 2023 | 1 |
| APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therape [PMID:33340485] | Serrano-Pozo A, Das S, Hyman BT | Lancet Neurol | 2021 | 1 |
| Lysosome-targeting chimaeras for degradation of extracellular proteins. [PMID:32728216] | Banik SM, Pedram K, Wisnovsky S, Ahn G, | Nature | 2020 | 1 |
| Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. [PMID:31564456] | Long JM, Holtzman DM | Cell | 2019 | 1 |
| Selective Silencing of TDP-43 P. G376D Mutation Reverses Key Amyotrophic Lateral [PMID:41897327] | Romano R, Ruotolo G, Perrone F, Tomasell | Biomolecules | 2026 | 0 |
| Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associate [PMID:41905188] | Cetindag AC, Schipke CG, Esselmann H, Kr | The journal of prevention of A | 2026 | 0 |
| Modulation of apolipoprotein E receptor-2 by ApoE4, amyloid β-peptide, reelin, a [PMID:41858499] | ["Barger S", "Moerman-Herzog A"] | Frontiers in molecular neurosc | 2026 | 0 |
| Chemical and Molecular Strategies in Restoring Autophagic Flux in TDP-43 Protein [PMID:41900026] | Jamerlan A, Hulme J | Molecules (Basel, Switzerland) | 2026 | 0 |
| ASS1 Promotes Atherosclerotic Inflammation Through the NLRP3/IL-33/ST2 Axis in O [PMID:41914296] | Wu S, Han F, Qiao Z, Yuan S, Bian X, Zha | Frontiers in bioscience (Landm | 2026 | 0 |
| Axonal transport impairment as an upstream mechanism in amyotrophic lateral scle [PMID:41890591] | Gabbay U | Frontiers in neuroscience | 2026 | 0 |
| CRISPR-based correction of apolipoprotein E4 in Alzheimer's disease: Therapeutic [PMID:41812941] | ["Wang M", "Niu D", "Zhang Q", "Tang Y", | International journal of biolo | 2026 | 0 |
| Defining RNA oligonucleotides that reverse deleterious phase transitions of RNA- [PMID:41512823] | ["Guo L", "Mann J", "Mauna J", "Copley K | Molecular cell | 2026 | 0 |
Multi-agent debates referencing this entity
active · Rounds: 7 · Score: 0.00 · 2026-04-26
closed · Rounds: 4 · Score: 0.76 · 2026-04-16
Hypotheses and analyses mentioning PET in their description or question text
Score: 0.640 · neurodegeneration · 2026-04-02
## Mechanistic Overview Glycine-Rich Domain Competitive Inhibition starts from the claim that modulating TARDBP within t
Score: 0.610 · neurodegeneration · 2026-04-22
## Mechanistic Overview H2: H3K9me3 Heterochromatin Collapse Enables Cryptic Transcription of Repetitive Elements starts
Score: 0.591 · neurodegeneration · 2026-04-16
**Molecular Mechanism and Rationale** The TREM2-C1Q competitive binding hypothesis centers on the intricate molecular i
Score: 0.590 · neurodegeneration · 2026-04-21
**Molecular Mechanism and Rationale** The hypothesis centers on the critical role of G3BP1 (Ras GTPase-activating prote
Score: 0.590 · neurodegeneration · 2026-04-25
TREM2-activated microglia limit neuritic plaque tau spread around amyloid plaques through enhanced phagocytosis of extra
Score: 0.560 · biomarkers · 2026-04-22
## Mechanistic Overview P2X7R PET Imaging for NLRP3 Inflammasome-Associated Priming starts from the claim that modulatin
Score: 0.530 · biomarkers · 2026-04-22
## Mechanistic Overview TSPO PET Kinetic Modeling for Priming State Discrimination starts from the claim that modulating
Score: 0.510 · neurodegeneration · 2026-04-22
## Mechanistic Overview Soluble GAG-Mimetic Peptides Compete with HSPG for Tau Seed Binding and Prevent Cellular Uptake
Score: 0.500 · biomarkers · 2026-04-22
## Mechanistic Overview CX3CR1 PET with Nano-bodies for Microglial Surveillance State Mapping starts from the claim that
Score: 0.500 · neurodegeneration · 2026-04-21
## Mechanistic Overview Shift AQP4 Isoform/OAP Assembly Toward Clearance-Competent Autoantibody-Less-Clustered State sta
Score: 0.490 · molecular neurobiology · 2026-04-25
lncRNA-0021 may not be uniquely specific at the physical binding level; instead, its apparent selectivity for mmu-miR-63
Score: 0.465 · neurodegeneration · 2026-04-02
Synthetic RNA aptamers designed to competitively bind TDP-43's RNA recognition motifs could prevent its interaction with